Brightsurf Science News & Current Events

May 11, 2013
Study shows lower rate of inappropriate shocks in patients with Sorin dual chamber ICD devices
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced findings from the landmark OPTION study1 demonstrating that patients with Sorin dual-chamber implantable cardioverter defibrillators experienced a significantly lower incidence of inappropriate shocks compared with patients with standard single-chamber devices (4.3 percent vs.10.3 percent, p=0.015).

Extremely low 90-day cardiac device infection rates with TYRX antibacterial envelope use
Use of TYRX, Inc.'s AIGISRx® Antibacterial Envelope reduced major infection rates over 90 percent in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacements compared to similar high-risk cohorts, according to CITADEL & CENTURION study results.

Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation
Researchers at the Intermountain Heart Institute at Intermountain Medical Center have developed a new 3-D technology that for the first time allows cardiologists the ability to see the precise source of atrial fibrillation in the heart -- a breakthrough for a condition that affects nearly three million Americans.

World first clinical trial supports use of Kava to treat anxiety
A world-first completed clinical study by an Australian team has found Kava, a medicinal South Pacific plant, significantly reduced the symptoms of people suffering anxiety.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.